![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/7b51103a-2479-4c6a-aa85-4bc567af6d15/gr3.gif)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/43ab3166-74af-4b76-8c27-8d7757560df6/gr4.gif)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/169313d7-3d23-416f-a299-9910fa42ee18/gr4_lrg.gif)